Periungual pyogenic granulomas after ravulizumab therapy in a child with acute myelomonocytic leukemia treated with hematopoietic stem cell transplant

Development of periungual pyogenic granulomas (pPGs) has been associated with several systemic treatments, including retinoids, taxanes, epidermal growth factor receptor inhibitors, and vascular endothelial growth factor inhibitors. We present the case of an 8‐year‐old girl with a personal history o...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology 2024-09, Vol.41 (5), p.940-941
Main Authors: Iznardo, Helena, López‐Torija, Ivan, Mateu‐Arrom, Laura, Escribano‐Sanz, Pablo, Puig, Lluís, Roé, Esther
Format: Article
Language:English
Subjects:
Acute myelomonocytic leukemia
Hematopoietic stem cells
Monoclonal antibodies
Myelomonocytic leukemia
periungual pyogenic granuloma
ravulizumab
Retinoids
Stem cell transplantation
thrombotic microangiopathy
Vascular endothelial growth factor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Development of periungual pyogenic granulomas (pPGs) has been associated with several systemic treatments, including retinoids, taxanes, epidermal growth factor receptor inhibitors, and vascular endothelial growth factor inhibitors. We present the case of an 8‐year‐old girl with a personal history of acute myelomonocytic leukemia treated with a haploidentical hematopoietic stem cell transplant who developed pPGs 2 months after starting ravulizumab. Ravulizumab is a monoclonal antibody directed against C5 protein. No previous reports of pPGs development have been described with ravulizumab.
ISSN:0736-8046
1525-1470
1525-1470
DOI:10.1111/pde.15675